Dr Lal Pathlabs

Stocks gaining momentum? Here's why Escorts, Hudco, 3 others are on radar

Technical charts show Escorts, Hudco, Dr Lal PathLabs, Force Motors and Godrej Consumer were trading above the higher-end of the Bollinger Bands on the daily scale; and can potentially rally up to 23%

Dr Lal PathLabs Q2 results: PAT up 16.4% at ₹152 crore, revenue rises 11%

Diagnostics chain declares ₹7 per share interim dividend, 1:1 bonus issue

Will Apollo, Max, Metropolis outshine peers in Q2? Here's what analysts say

Domestic brokerage firm Nuvama analysts forecast a modest sequential slowdown but a healthy ~17 per cent year-on-year (Y-o-Y) Ebitda growth, led by hospitals and diagnostics.

Dr. Lal Path Labs rises 3% on adopting new AI cancer diagnostic tool

Dr. Lal Path Labs shares rose 3.2 per cent on Wednesday, after it became the first laboratory in the country to adopt a deep learning-based AI module to detect lymph node metastas

Dividend, bonus, rights issue, demerger: BoB, Concor & 23 others in focus

Bank of Baroda, Concor, HDFC Asset Management Company, and 22 others will be in focus today as they will trade ex-date on Friday, June 6, 2025

These 5 pharma stocks can fall up to 12% as technical charts flag caution

Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for.

Dr Lal PathLabs Q4 profit rises 81% on volume growth, geographic expansion

The company's revenue from operations also rose to Rs 603 crore in Q4FY25, a 10.5 per cent Y-o-Y growth from Rs 545 crore reported in Q4FY24

Dr Lal Path Labs Q4FY25 results: Net profit rises 83.2% to ₹155 crore

The company's consolidated net profit jumped 83.2 per cent year-on-year to Rs 1.55 billion (about $18 million) in the quarter ended March 31

Dr Lal Q3FY25 results: PAT jumps 19% to Rs 98 crore as volumes grow

As for Suburban Diagnostics, an arm of Dr Lal Pathlabs, revenue growth was 9.2 per cent in Q3

Dr Lal Path Labs Q3FY25 results: Net profit jumps 19% to Rs 96.7 crore

The company's consolidated net profit rose to Rs 96.7 crore ($11.2 million) in the three months to Dec. 31, from Rs 81.3 crore a year earlier, but fell short of analysts' estimate of Rs 97.69 crore

HMPV scare: Vijaya, Dr Lal Path, healthcare stocks in focus; Time to buy?

Apollo Hospitals, Vijaya Diagnostic and Narayana Hrudayalaya have given a fresh breakout on the daily scale. Charts show that these 5 healthcare related shares can rally up to 11 per cent.

F&O Market: Union Bank, Dabur see short build-up as Nifty tumbles 300pts

Union Bank stock futures plunged nearly 8% on the back of 54% increase in OI. On the other hand, Dr. Lal Path Labs and Metropolis Health witnessed long build-up on Monday; shows derivatives data.

Diagnostic demand rises in towns; organised players lead expansion plans

The Healthcare Federation of India reports that over 50 per cent of aspirational districts identified by NITI Aayog, which lack essential infrastructure, are served by diagnostic chains

Dr Lal PathLabs up 4% on strong September qtr results; more details here

The uptick in Dr Lal PathLabs's share price came on the back of a healthy September quarter of financial year 2025 (Q2FY25) earnings

Dr Lal PathLabs Q2 results: Profit up by 18.2%, revenue rises by 9.8%

The company, which operates 280 labs across India and is on track to open 15-20 new labs this year as part of its expansion efforts, is also exploring acquisitions in southern India

Dr Lal Path Labs Q2FY25 results: Net profit jumps 18% to Rs 129 cr

The company's consolidated net profit increased 18 per cent year-over-year to Rs 129 crore ($15.4 million), increasing for the sixth quarter in a row

Dr Lal PathLabs Q1 results: Net profit up by 29.1%, revenue rises by 11.3%

The company's revenue from operations rose to Rs 602 crore in Q1FY25, an 11.3 per cent Y-o-Y growth from Rs 541 crore reported in Q1FY24

Dr Lal PathLabs Q1FY25 results: Net profit rises 28% to Rs 106 cr

Consolidated net profit rose 28 per cent to Rs 106 cr (around $13 million) for the quarter ended June 30, beating analysts' estimate of Rs 99.27 cr, per LSEG

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.

Deepening presence in Tier-III may be Dr Lal PathLabs' growth pill

Manchanda highlights that the 'white-spaces' for them are going deeper in strong markets